Alice P. Chen - Concepedia

Author

Alice P. Chen

Also Known As

, A. Chen, ALICE CHEN, ALICE P. CHEN, Alice Chen, Alice P Chen, Alice P. Chen, Brandon Brown, Chen, Alice, Chen, Alice P

757

Publications

18.6K

Citations

H-Index

256

Concepts

All Affiliations

National Cancer Institute Center for Cancer Research National Institutes of Health Frederick National Laboratory for Cancer Research The University of Texas MD Anderson Cancer Center

About

Alice P. Chen is an author at National Cancer Institute specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	85	3.9K
2	Health Sciences	12	14	575
3	Engineering	8	8	223
4	Education	1	1	215
5	Law	1	1	1.8K

Alice P. Chen

182

Publications

15.8K

Citations

H-Index

Page 1

	Year	Citations
Treatment of HCV Infection by Targeting MicroRNA Harry L.A. Janssen, Hendrik W. Reesink, Eric Lawitz, New England Journal of Medicine	2013	2.2K
RECIST 1.1—Update and clarification: From the RECIST committee Lawrence H. Schwartz, Saskia Litière, Elisabeth G.E. de Vries, European Journal of Cancer Public PolicyRecist 1.1—UpdateLawAdministrative LawPolicy Process	2016	1.8K
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer M. Catherine Pietanza, Saiama N. Waqar, Lee M. Krug, Journal of Clinical Oncology	2018	387
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline <i>BRCA/PALB2</i> Mutation Eileen M. O’Reilly, Jonathan W. Lee, Mark M. Zalupski, Journal of Clinical Oncology	2020	383
Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0 Alice P. Chen, Ann Setser, Milan J. Anadkat, Journal of the American Academy of Dermatology Dermatologic Adverse EventsCancer TreatmentsMedicineAdverse EventClinical Epidemiology	2012	349
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies Shivaani Kummar, Robert J. Kinders, Martin Gutierrez, Journal of Clinical Oncology	2009	324
Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors T. Khanh, Deborah Wilsker, Jiuping Ji, Journal of Clinical Oncology	2015	317
Overexpression of Phytochelatin Synthase in Arabidopsis Leads to Enhanced Arsenic Tolerance and Cadmium Hypersensitivity Yujing Li, Om Parkash Dhankher, Laura Carreira, Plant and Cell Physiology	2004	282
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) Keith T. Flaherty, Robert J. Gray, Alice P. Chen, Journal of Clinical Oncology	2020	281
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF<sup>V600E</sup></i> Mutations: Results of the NCI-MATCH Trial Subprotocol H April K.S. Salama, Shuli Li, Erin Macrae, Journal of Clinical Oncology	2020	277

Page 1